SB 221

Drug Profile

SB 221

Alternative Names: SB-221; Tensostat

Latest Information Update: 09 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SunTen Phytotech
  • Developer Lumosa Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cardiovascular disorders

Highest Development Phases

  • Discontinued Cardiovascular disorders; Dyslipidaemias; Essential hypertension

Most Recent Events

  • 08 Sep 2017 Discontinued - Phase-II for Cardiovascular disorders in Taiwan (PO)
  • 08 Sep 2017 Discontinued - Phase-II for Dyslipidaemias in Taiwan (PO)
  • 08 Sep 2017 Discontinued - Phase-II for Essential hypertension in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top